Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 9/20 | 0.61 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.57 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.57 |
| ▸ | CTSL | P07711 | 3/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.56 |
| ▸ | CTSK | P43235 | 3/20 | 0.56 |
| ▸ | CTSH | P09668 | 1/20 | 0.56 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6041194 | 1.00 | CXCR4 (0.61) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL29520254 | 0.95 | KISS1R (0.62) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL29978571 | 0.94 | CXCR4 (0.59) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL30945042 | 0.93 | CXCR4 (0.66) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL29380582 | 0.93 | CXCR4 (0.64) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL30288110 | 0.93 | KISS1R (0.61) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL31506622 | 0.92 | DPP3 (0.61) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL31005883 | 0.92 | KISS1R (0.57) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL31452905 | 0.91 | CXCR4 (0.62) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL38652302 | 0.90 | CXCR4 (0.59) | CXCR4NTSR2NTSR1SORT1KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060040348-A1 | Methods for producing and purifying recombinant alpha-L-iduronidase | ROYALTY SECURITIZATION TRUST I | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040348-A1 | Methods for producing and purifying recombinant alpha-L-iduronidase | IDUA, ENGASE, HEXA | CXCR4 3375/4885NTSR2 3898/4885NTSR1 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.